GLP-1 drugs projected to improve annual mortality by 0.2%-0.5% over two decades

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have transcended their initial role in type 2 diabetes mellitus management, now showing broad therapeutic potential across numerous metabolic and cardiorenal indications, including obesity. Their proven ability to reduce cardiovascular events and improve glycemic control suggests a significant impact on overall morbidity and mortality. This expanding utility makes GLP-1 drugs a critical consideration for life insurers, who need to accurately assess long-term mortality risk and adapt underwriting practices to reflect these emerging benefits.

Researchers conducted a large-scale mortality study to estimate the long-term impact of GLP-1 drugs on annual mortality improvement. This analytical work synthesized existing evidence and epidemiological data to project potential mortality reductions over a 20-year period. The study focused on quantifying the aggregate mortality benefits attributable to widespread GLP-1 drug use, specifically considering implications for life insurance underwriting and product development. The primary endpoint was the estimated percentage of annual mortality improvement.

The large-scale mortality study projected that GLP-1 drugs could drive a significant 0.2%-0.5% annual mortality improvement, realized over a 20-year period. This finding highlights the substantial population-level health benefits associated with these therapies. > The study identified that GLP-1 drugs may drive 0.2%-0.5% annual mortality improvement, realized over a 20-year period, presenting opportunities for carriers to transform how they assess metabolic risk. Furthermore, the analysis emphasized that low patient adherence could significantly limit these long-term mortality benefits. The study also underscored the critical role of electronic health records (EHR) in accurately assessing individual metabolic risk profiles for underwriting purposes, suggesting a need for nuanced program design due to variations in individual adherence and behavioral changes.